How rofecoxib’s prostaglandin effects change stomach risk
Rofecoxib (a COX-2–selective NSAID) reduces the production of prostaglandins made by the COX-2 pathway. That matters for stomach health because prostaglandins normally help protect the gastric lining. When those protective prostaglandins are reduced, the stomach is more vulnerable to irritation and ulceration. COX-2 selectivity is designed to shift inhibition away from the COX-1 pathway that is strongly linked to this protective effect, lowering the likelihood of stomach damage compared with nonselective NSAIDs. [1]
What “lower prostaglandin suppression” means for ulcers and irritation
COX-1–derived prostaglandins help maintain the stomach’s defenses by supporting mucus and bicarbonate secretion and helping maintain mucosal blood flow. Because rofecoxib targets COX-2 more than COX-1, it tends to preserve more of the COX-1–dependent protective prostaglandin activity than drugs that inhibit both COX-1 and COX-2. That is the main reason people associate COX-2–selective inhibition with fewer gastroduodenal side effects. [1]
Does reducing prostaglandins always help the stomach?
Not necessarily. Prostaglandins also drive inflammation-related symptoms, so reducing them can relieve pain and inflammation. The benefit for stomach health comes from which prostaglandins are affected: rofecoxib aims to inhibit COX-2–mediated prostaglandins tied to pain/inflammation more than COX-1–mediated prostaglandins tied to gastric protection. If COX-1 protective activity is reduced too much, ulcer and bleeding risk rises; rofecoxib’s selectivity is meant to reduce that risk. [1]
How this compares with nonselective NSAIDs
Nonselective NSAIDs inhibit both COX-1 and COX-2, which lowers prostaglandins involved in stomach protection and increases the chance of ulcers and bleeding. Rofecoxib’s COX-2 selectivity means it generally causes less interruption of COX-1–dependent gastric defense prostaglandins than nonselective NSAIDs, which is the key stomach-health mechanism behind its reputation. [1]
What patients should watch for anyway
Even COX-2–selective NSAIDs can still carry gastrointestinal risks, especially with higher doses or other risk factors (for example, prior ulcers or concomitant medications). The prostaglandin explanation is mainly about relative risk differences tied to COX-1 versus COX-2 activity, not a guarantee of no harm. [1]
Sources
- https://www.drugs.com/rofecoxib.html